High proportions of VLA‐5 immature myeloma cells correlated well with poor response to treatment in multiple myeloma

Michio M. Kawano, Maged S. Mahmoud, Naihui Huang, Igor A. Lisukov, Keiichiro Mihara, Takako Tsujimoto, Atsushi Kuramoto

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Summary. Using two‐colour phenotypic analysis with anti‐CD38 antibody, human myeloma cells can be classified into VLA‐5 immature and VLA‐5+ mature cells. We examined the relationship between variations of these subpopulations and clinical responses during treatment in multiple myeloma (MM). 39 patients with MM were treated with combined chemotherapy. First estimation of clinical responses after induction therapy showed that early clinical responses were correlated with the percentage of immature myeloma cells present after induction therapy (P < 0.01), not at diagnosis. After three courses of cyclic maintenance therapy, immature myeloma cells significantly decreased in proportion along with a decrease in total myeloma cells in maintained or more responsive cases (P < 0.01). On the other hand, immature myeloma cells were still found in high proportions in non‐responsive cases with no change (NC) or minor response (MR) (P < 0.01). Furthermore, in relapsing cases from partial response (PR) or progressive disease (PD) from non‐responsive cases, immature myeloma cells increased markedly. Therefore these results show that high proportions of VLA‐5 immature myeloma cells remaining after induction therapy and during maintenance therapy correlate well with a declining clinical course of MM during maintenance therapy.

Original languageEnglish
Pages (from-to)860-864
Number of pages5
JournalBritish Journal of Haematology
Volume91
Issue number4
DOIs
Publication statusPublished - 12-1995
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint

Dive into the research topics of 'High proportions of VLA‐5<sup>−</sup> immature myeloma cells correlated well with poor response to treatment in multiple myeloma'. Together they form a unique fingerprint.

Cite this